A longevity program embedded inside existing primary-care practices rather than a standalone clinic, betting that distribution through docs patients already trust is a cheaper path to scale than building destination longevity centers. Working name "Thrive at 85," the concept equips a primary-care physician to layer a longevity offering onto 40–50 self-selected patients at roughly $4,500–$5,000 per year, above MDVIP's $2,000–$3,000 tier but with a richer wrap: full Quest labs, DEXA and VO2 max at entry, a registered dietitian and exercise physiologist at onboarding, and an ongoing health coach who owns the patient relationship, with an AI-assisted back end for diet and exercise protocols (Internal, note recCQk2HGFcG31ao5, 2026-07-15). The wedge is distribution and unit economics: docs earn roughly $40,000–$50,000 of incremental annual income for about 60 hours of work, and members pay upfront, so the model is cash-flow positive ahead of EBITDA in its first three years.
This is a concept, not a company. As of the 2026-07-15 catch-up call, founder Kip Hallman, a StoryHouse LP and 20-plus-year healthcare-services operator, has the thesis and the sector credibility but no technical co-founder, no named clinical lead (current physician advisors have conflicts), and no validated pilot; Josh's own note flags uncertainty about whether Kip has the early-stage startup chops to build, scale, and exit against a very heated longevity field (Internal, note recCQk2HGFcG31ao5). Kip is targeting a small friends-and-family round of about $1M and projects roughly 15x for early investors if the model validates (Internal, note). StoryHouse's engagement to date is relationship-level: offering to share physician profiles and introductions for a clinical lead and to weigh in on the AI and tech stack. Against digital longevity players raising nine-figure rounds (Function Health closed a $298M Series B at a $2.5B valuation in November 2025) (Web), the differentiator here is capital efficiency and an untapped distribution channel, not technology or a team that yet exists.
The addressable wedge sits at the intersection of the longevity-clinic market (about $6.0B in 2026, growing 12.2% to roughly $9.6B by 2030) (Web) and the far larger concierge / membership primary-care base that MDVIP has already proven at ~362,000 members across ~1,100 physicians (Web). The relevant thesis question is not market size but density: whether a typical 2,000-patient primary-care panel actually contains 30–50 longevity-motivated patients willing to pay ~$4,500–$5,000 per year (Internal, note recCQk2HGFcG31ao5). Concierge medicine is entering its first private-equity consolidation wave, a tailwind for both demand and eventual exit optionality (Web).
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Thrive at 85 | Longevity layered into existing primary-care panels, ~$4.5–5K/yr, coach-led | Pre-round, ~$1M F&F | — |
| MDVIP | Traditional concierge primary care, $2–3K/yr; strong physical but no longevity focus | PE-owned (Goldman AM + Charlesbank, 2021) | Purpose-built for longevity vs. generalist concierge |
| Function Health | Digital longevity testing platform, ~$500/yr, 100+ biomarkers | $298M Series B @ $2.5B (Nov 2025) | Care + coaching embedded in a doc relationship vs. testing-only |
| Superpower | Consumer longevity testing, $499/yr, 100+ biomarkers | $28M raised, 150K waitlist | Physician-embedded model vs. D2C self-serve |
| Fountain Life | High-end clinic, whole-body MRI and advanced imaging | $19,500+/yr premium | An order of magnitude cheaper, embedded not destination |
| Biograph | Peter Attia-affiliated preventative clinic, total-body imaging | Premium concierge | Actionable coaching vs. testing-heavy (Kip's stated critique) |
Moat: the only real defensibility today is the distribution wedge, recruiting and equity-aligning existing primary-care docs so patient acquisition rides on trust that already exists; there is no proprietary technology, clinical protocol, or team advantage yet, and the AI back end described is explicitly lightweight (Internal, note recCQk2HGFcG31ao5).
No traction data. This is a pre-formation concept as of the 2026-07-15 call: no product, no pilot physicians, no enrolled patients, no revenue, and no technical co-founder yet (Internal, note recCQk2HGFcG31ao5).
The clearest exit analog is concierge consolidation: MDVIP, majority-owned by Goldman Sachs Asset Management and Charlesbank since 2021, is expected to run a banker process in 2026–2027 that will reset pricing for every concierge transaction that follows (Web), and Revelstoke and Acrisure-backed platforms are already building rollups (Web). On the venture side, Function Health's $2.5B mark shows how richly the category is valued when scaled (Web). The founder's ~15x case is a projection contingent on unproven model validation, not a diligenced figure (Internal, note recCQk2HGFcG31ao5); at a ~$1M concept round, even a modest membership rollup outcome could return the check, but nothing about the return is yet underwritable.
Catch-up call with StoryHouse LP Kip Hallman, who walked through an early-stage concept to embed a longevity program inside existing primary-care practices. Strong operator enthusiasm, but no technical co-founder and open questions about early-stage execution against heavy competition.
Summary of call: Good catch up with LP Kip Hallman. He is very excited about this longevity idea, but does not yet have the technical co-founder necessary, and Josh is unsure whether he has the early-stage startup chops required to aggressively build, scale, and exit relative to competition in a very heated longevity space.
Kip's background and motivation: Senior operator with 20-plus years in healthcare services (correctional health, MDVIP-adjacent). Now part-time / board-only at Wellpath, giving him time to develop a new venture. Personal obsession with active longevity (heli-skiing, surfing; wants to stay active into his 80s and 90s). Dissatisfied with existing options: high-end concierge (Peter Attia-style) at $20K–$100K is testing-heavy and not actionable enough; peptides/hormones tracks are substance-focused; MDVIP gives a great physical but no longevity focus, and he left his own MDVIP doc six months ago.
Thrive at 85, the model: Embed a longevity program inside existing primary-care practices, ~40–50 patients per doc, at ~$4,500–$5,000/year (above MDVIP's $2K–$3K but a richer offering). Doc economics ~$1,000–$1,500/patient annually, ~$40K–$50K extra per year for ~60 hours of work. The doc runs a comprehensive annual physical reoriented to longevity markers (grip strength, etc.), stays informed on patient progress, and is available for escalations. Thrive at 85 delivers full labs (Quest), DEXA scan and VO2 max at entry, a registered dietitian and exercise physiologist at onboarding, an ongoing health coach (biweekly check-ins, primary patient relationship), a wearable-data dashboard for coaches and doc, and an AI-assisted back end for diet/exercise protocols with human coaches for relationship and accountability. Target markets: San Diego, San Francisco, Austin, Nashville. Founding docs receive equity as early adopters.
Business model and financials: Cash-efficient, members pay upfront, working capital front-loaded; cash flow exceeds EBITDA in the first three years. No insurance billing, direct-pay only (members likely straight Medicare or well-insured). Simple cost structure: employed health coaches, contracted local DEXA/VO2 max, Quest labs, and doc fees. Targeting a small friends-and-family round of ~$1M; projected ~15x for early investors if the model validates. Key open question: do enough longevity-motivated patients (30–50 per doc) exist within a typical 2,000-patient primary-care panel in target markets?
Where Kip needs help: a clinical lead who can formalize protocols and be named publicly (current advisors have conflicts); a tech stack (integrated patient dashboard, wearable-data aggregation, lightweight AI for diet/exercise) built efficiently rather than over-engineered; and thesis validation via pilot docs before full build-out (a chicken-and-egg problem). StoryHouse offered to help with physician profiles and introductions and to share thoughts on the AI/tech stack.